Skip to main content
Finanzoo GmbH Finanzoo GmbH

Oncolytics Biotech Value Stock - Dividend - Research Selection

Oncolytics biotech

ISIN: CA6823108759 , WKN: A2JMW5
Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!

How our site works ...

✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month 
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.


Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet

Description of the company

Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,

NEWS


Oncolytics Biotech (ONCY) Loses 8.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

2025-12-03
The heavy selling pressure might have exhausted for Oncolytics Biotech (ONCY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Yahoo

Oncolytics Biotech® Provides Update on Special Meeting of Shareholders

2025-11-20
SAN DIEGO, November 20, 2025--Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced that it has cancelled and will reschedule its special meeting of shareholders (the "Special Meeting"), as described in its news release dated October 20, 2025, which was to be held on December 15, 2025. The Special Meeting is being rescheduled due to delays at the Securities and Exchange Commission caused by the recen
Yahoo

All You Need to Know About Oncolytics Biotech (ONCY) Rating Upgrade to Buy

2025-11-19
Oncolytics Biotech (ONCY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Yahoo

Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer

2025-11-19
SAN DIEGO, November 19, 2025--Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced alignment with the U.S. Food and Drug Administration ("FDA") regarding the design of its pivotal study of pelareorep in combination with standard-of-care therapy for the first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).
Yahoo

Oncolytics Biotech® Establishes Gastrointestinal Tumor Scientific Advisory Board to Advance Pelareorep as a Platform Immunotherapy

2025-11-04
SAN DIEGO, November 04, 2025--Oncolytics Biotech® Establishes Gastrointestinal Tumor Scientific Advisory Board to Advance Pelareorep as a Platform Immunotherapy
Yahoo

Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care

2025-10-28
Oncolytics Biotech® Inc. (NASDAQ: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced updated results from the single-arm SCAC cohort of the GOBLET study evaluating pelareorep in combination with atezolizumab (Tecentriq®) in patients with ≥2L metastatic SCAC. Patients from this cohort continue to be followed, and additional efficacy data are expected to be reported.
Yahoo

Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada

2025-10-20
Oncolytics Biotech® Inc. (NASDAQ: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced it has filed a registration statement on Form F-4 with the Securities and Exchange Commission (the "SEC") that includes a preliminary management circular/prospectus and other relevant documents related to various proposals contained therein, and has plans to hold a Special Meeting of Shareholders (the "Special Meeting") to vote on, among other thi
Yahoo

Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study

2025-09-29
Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced an update on the proposed design of its planned registration-directed clinical trial in first-line pancreatic ductal adenocarcinoma (PDAC). The Company is currently scheduled to meet with the U.S. Food and Drug Administration (FDA) in mid-November 2025 to advance study details.
Yahoo

Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion

2025-09-16
Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced updates on enrollment progress, U.S. site expansion, and expected data readouts from the ongoing GOBLET trial evaluating pelareorep in gastrointestinal cancers. The study is supported in part by a grant from the Pancreatic Cancer Action Network (PanCAN).
Yahoo